An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
aTyr Pharma to Participate in April Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
aTyr Pharma, Inc. (Nasdaq: LIFE) will participate in two investor conferences in April 2024. The company focuses on developing innovative medicines from its tRNA synthetase platform. Their lead candidate, efzofitimod, targets interstitial lung disease.
Positive
None.
Negative
None.
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.
Details of the conferences appear below:
Conference: Evercore ISI Diamonds in the Rough Webinar Day Date: Thursday, April 4, 2024 Time: 10:30am EDT Location: Virtual Format: Corporate Presentation with Q&A Session
Conference: Piper Sandler Spring Biopharma Symposium Date: Wednesday, April 17, 2024 Location: Everett, MA Format: 1x1 Investor Meetings
For more information on how to register, please contact your Evercore ISI or Piper Sandler representative.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com
aTyr Pharma will participate in the Evercore ISI Diamonds in the Rough Webinar on Thursday, April 4, 2024, at 10:30am EDT.
aTyr Pharma's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for interstitial lung disease.
aTyr Pharma's discovery platform focuses on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases.
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
